Entering text into the input field will update the search result below

Mainz Biomed contacts DCN Dx to support a clinical trial for its colorectal cancer test

Jan. 19, 2022 7:30 AM ETMainz Biomed N.V. (MYNZ) StockBy: Dulan Lokuwithana, SA News Editor
  • Mainz Biomed (NASDAQ:MYNZ) has obtained the services of DCN Dx to support the company in its efforts to run a European-based clinical trial to evaluate ColoAlert, its detection test for colorectal cancer.
  • As an international developer of point-of-care diagnostics, DCN Dx

Recommended For You

More Trending News

About MYNZ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MYNZ--
Mainz Biomed N.V.